Beizray Patent Expiration

Beizray is a drug owned by Zhuhai Beihai Biotech Co Ltd. It is protected by 3 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 16, 2036. Details of Beizray's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11419842 Neutral pH compositions of Docetaxel and human serum albumin
May, 2036

(11 years from now)

Active
US12090134 Neutral pH compositions of docetaxel and human serum albumin
May, 2036

(11 years from now)

Active
US12090135 Neutral pH compositions of docetaxel and human serum albumin
May, 2036

(11 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Beizray is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Beizray's family patents as well as insights into ongoing legal events on those patents.

Beizray's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Beizray's generic launch date based on the expiry of its last outstanding patent is estimated to be May 16, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Beizray Generic API suppliers:

Docetaxel is the generic name for the brand Beizray. 15 different companies have already filed for the generic of Beizray, with Hengrui Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Beizray's generic

Alternative Brands for Beizray

There are several other brand drugs using the same active ingredient (Docetaxel) as Beizray. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Avyxa Holdings
Docivyx
Sanofi Aventis Us
Taxotere
Shilpa
Docetaxel


Apart from brand drugs containing the same ingredient, some generics have also been filed for Docetaxel, Beizray's active ingredient. Check the complete list of approved generic manufacturers for Beizray





About Beizray

Beizray is a drug owned by Zhuhai Beihai Biotech Co Ltd. Beizray uses Docetaxel as an active ingredient. Beizray was launched by Zhuhai in 2024.

Approval Date:

Beizray was approved by FDA for market use on 23 October, 2024.

Active Ingredient:

Beizray uses Docetaxel as the active ingredient. Check out other Drugs and Companies using Docetaxel ingredient

Dosage:

Beizray is available in solution form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
80MG/4ML (20MG/ML) SOLUTION Prescription INTRAVENOUS